Having been over a year since COVID-19 was officially declared a pandemic, we here at ABclonal have had the chance to compile and explore a wide range of information, resources, and breakthroughs related to the novel coronavirus through our blogs. Below, we've organized and selected five recommended pieces of reading related to COVID-19, covering topics including asymptomatic cases, the different detection methods (PCR vs. antibody testing), as well as a one-year-mark review of the impact of COVID-19.
It has now been over a year since March 2020, when the World Health Organization determined that the growing spread of COVID-19 would be officially characterized as a global pandemic. The year that followed challenged humanity with a public health crisis on a scale that few could even imagine, with far-reaching social and economic impacts still being felt across the globe. And yet, this past year also brought out the best in many of us, with medical professionals diligently fighting the pandemic on the front lines and researchers collaborating to progress our global recovery. Owing to the relentless work of researchers making breakthroughs in vaccine research, it appears that the long road to recovery has finally begun.
In a press release on August 26th, 2020, Abbott Laboratories announced that they were issued an emergency use authorization (EUA) by the FDA for their new, rapid point-of-care COVID-19 antigen test. Branded as the “BinaxNOW COVID-19 Ag Card”, the test is unique compared to the more prevalent molecular-based detection tests for COVID-19 in that it utilizes a lateral flow assay, similar to traditional over-the-counter pregnancy tests. Contained in a portable, credit-card sized device, Abbott claims that the test can deliver results in as little as 15 minutes, representing a significant reduction in time compared to RT-PCR-based tests that have turnaround times on a scale of hours rather than minutes.
During these past few months, the push to discover effective treatments and vaccines against COVID-19 has largely overshadowed another vitally important aspect of drug development: drug pricing. Let’s take a look at a recent example from pharma giant Gilead, who recently announced the pricing for its promising COVID-19 treatment remdesivir.
In direct support of the fight against the novel coronavirus and the world's effort to understand more about the mechanisms of the COVID-19 disease, we're proud to announce the arrival of our SARS-CoV-2 Neutralizing Antibody.
Over these past few months, we here at ABclonal have been working diligently to continue supplying necessary reagents to researchers, clinicians, and companies worldwide to facilitate their efforts during the COVID-19 pandemic. In direct support of that goal, we’re proud to introduce our new, comprehensive line of SARS-CoV-2 ELISA kits.